The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Roche says the move marks a step forward in its digital transformation strategy
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Surgical site infections and antimicrobial resistance remain major challenges globally
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
